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 Cytochrome P450 enzymes are involved in the metabolism of foreign substances 
that are present within living organisms. These P450s are classified as Phase I 
metabolizing enzymes that are found mainly in the liver, they belong to a superfamily of 
heme containing monoxygenases that are required for metabolism for a number of 
xenobiotics. Mechanistic approach by these enzymes involves carrying out the oxidation 
of carbon and nitrogen groups usually resulting in the addition of an alcohol. Cytochrome 
P450 enzymes have been involved in the bioactivation of inactive compounds to active 
electrophiles that can contribute to the production of reactive oxygen species, such as 
superoxide, free radicals, and peroxides1. These ROS can contribute to oxidative stress, 
which leads to hepatic cell necrosis, lipid peroxidation, and DNA adduct formation. 
 This study focuses on two specific Cytochrome P450s, CYP2E1 and CYP2A6. 
These enzymes have shown to have one of the highest rates of uncoupling among all 
P450s, this uncoupling leads to the production of ROS. This study focuses on finding 
potential inhibitors that decrease the chances of these uncoupling reactions from 
occurring. Human, rat, and rabbit liver microsomes were used for these studies. A series 
of essential oils were screened with these P450s to determine their inhibitory affects on 
the enzyme. From these studies, tarragon (Artemisia dracunculus) and basil (Ocimum 
basilicum) showed the highest inhibitory affects on the enzyme. The major constituent 
for both these oils was estragole, this was also confirmed via GCMS testing, because of 
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this it was thought that it was a major reason to why the enzyme activity is being 
inhibited. With the initial screening data showing inhibition of CYP2E1 and CYP2A6, 
next goal was to determine how potent these oils were and what is the mode of inhibition, 
reversible or irreversible. The results of CYP2E1 and CYP2A6 with human, rat, and 
rabbit concluded that both essential oils and estragole inhibited the activity of the 
enzyme. Estragole was the most potent inhibitor of both enzymes in all 3 species. The KI 
value for estragole with CYP2E1 in humans was 22.4 µM, in rat 143 µM, and in rabbit 
108 µM. The KI value for estragole with CYP2A6 in humans was 27.5 µM and in rabbit 
was 49.3 µM. Results show that the mode of inhibition shown by both these essential oils 
and estragole was non-competitive and a reversible type of interaction occurred with both 
Cytochrome P450 enzymes. 
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CHAPTER I 
 
INTRODUCTION 
 
 
1.1.0 Cytochrome P450 Enzymes and Metabolism 
At any given time there are a number of foreign substances that are present within 
living organisms and the metabolism of these xenobiotics is important to maintain a 
homeostatic equilibrium. Enzymes are essential in the metabolism of these xenobiotics; 
there are two classes of enzymes that are involved in this process. They are described in 
general terms as Phase I and Phase II enzymes. Phase I is involved in oxidation and phase 
II in conjugation. Reactions of both phases cause compounds to become more 
hydrophilic, thus making it simpler for them to be readily eliminated through renal 
excretion. An important class of Phase I enzymes are the Cytochrome P40 enzymes, 
which belong to a superfamily of heme containing monoxygenases that are required for 
metabolism of number of endogenous and exogenous compounds. Xenobiotic 
metabolizing Cytochrome P450s are found in the liver and a variety of other mammalian 
tissue1. The overall mechanistic view is that Cytochrome P450s carry out the oxidation of 
carbon and nitrogen groups usually resulting in the addition of an alcohol.  
Cytochrome P450s are responsible for metabolism of most xenobiotics that enter 
the body. However, these enzymes are also involved in the bioactivation of inactive  
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compounds to active electrophiles that can be potential toxins to the liver1. When certain 
chemicals are bioactivated they can lead to cell necrosis and sometimes to cellular 
transformation that eventually results in cancer or in some instances damage to hepatic 
tissue. One such example of this is when acetaminophen is bioactivated to a highly 
reactive Quinone, N-acetyl-p-benzoquinone (NAPQI). NAPQI can produce reactive 
oxygen species (ROS) and covalently bind to cellular nucleophiles such as DNA, RNA, 
and proteins, which eventually results in cellular necrosis. Acetaminophen is known to 
cause liver failure (through hepatic necrosis) when taken in high concentrations, which 
leads to hepatotoxicity2. 
 
1.2.0 Properties of Cytochrome P450s 
There are approximately 60 Cytochrome P450 genes in the human body3. All 
Cytochrome P450 gene names start with a CYP, representing that they belong to the 
P450 family. Following this is a number, which specifies which gene family the enzyme 
is coming from, next is a letter representing the gene’s subfamily, and at the end a 
number is assigned to distinguish the specific gene within the subfamily. An example of 
this would be if we had a CYP P450 gene that is in-group 2, subfamily E, and gene 1 
would be written as CYP2E1. 
 With multiple studies showing how Cytochrome P450s are involved in the 
activation of xenobiotics, it is beneficial to reduce activity of such enzymes so the 
creation of toxic intermediates is decreased4. In order to fully understand the mechanistic 
properties of these enzymes it is important to study their molecular structure. The active 
!
! 3 
site is important in determining activity of these isoforms. A commonality between all 
CYP P450s enzyme is that they contain an iron atom at the core of the heme within the 
porphyrin ring. The reduction of this iron atom is the rate-limiting event of the overall 
reaction5.  
 
1.2.1 Cytochrome P450 Mechanisms 
  The catalytic cycle of P450s is essential to understanding how these isoforms 
function. Figure 1 is a depiction of the general reaction of all Cytochrome P450 enzymes. 
Starting from the first step of the mechanism, the substrate comes into the active site of 
the enzyme, which causes the displacement of the water molecule that is bound to the 
iron center. This displacement of water causes the ferric FeIII complex to be reduced, by 
an electron that is donated from Nicotinamide adenine dinucleotide phosphate (NADPH), 
to FeII. Once this reduction occurs, it allows molecular oxygen to come in and bind to the 
iron center, forming an iron-oxo complex. Upon the formation of this complex, it allows 
NADPH to donate a second electron to the system that reduces the oxygen. The oxygen 
molecule then goes through protonation that allows one of the oxygen molecules to be 
cleaved and leave the system in the form of a water molecule. Upon this an oxo-ferryl 
intermediate is formed (represented in step 6), this intermediate is highly reactive. The 
highly reactive oxo-ferryl complex allows the oxidation of the substrate to occur. Once 
the oxidation of the substrate happens, this allows a water molecule to come in and 
displace the newly formed product, and the catalytic cycle starts over again. In figure 2 it 
can be seen how this same catalytic cycle can lead down a different pathway when 
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uncoupling is exhibited. This leads to the production of reactive oxygen species such as 
peroxides and superoxide. ROS’s lead to oxidative stress, which ultimately can cause 
damage to cells, lipid peroxidation, and DNA adduct formation. Looking at figure 2 it 
can be seen how the dissociation of the peroxo-iron complex from stages 4 and 5 lead to 
the formation of this ROS’s. Once the peroxide and superoxide dissociates the iron goes 
is free to accept more electrons. 
 
 
Figure 1. Catalytic Cycle of Cytochrome P450s. The reaction depicts what happens 
from the point of entrance of the substrate into the active site. The overall outcome of this 
reaction is that the substrate is hydroxylated so it can be readily excreted from the living 
organism. 
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Figure 2. Uncoupling with CYP P450s. The catalytic cycle showing how reactive 
oxygen species are produced through uncoupling of iron-oxo complex in stages 3 and 4 
of the mechanism. 
 
 
1.2.2 O-Demethylation Reaction 
 CYP P450s carry out various types of chemical oxidation reactions that are 
dependent upon the substrate that is present. The o-demethylation reaction is one 
common reaction carried out by these P450 isozymes. This reaction involves a removal 
of a methyl group that is attached to an oxygen atom. As shown in figure 3, the substrate 
is hydroxylated via the P450 catalytic cycle. The position of the hydroxyl group causes 
an unstable hemi-acetal to form, which then rearranges and causes the demethylation 
reaction to occur. 
!
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Figure 3. O-Demethylation Reaction. It can be seen oxo-ferryl intermediate generated 
from the CYP P450 catalytic cycle is involved in oxidizing the terminal methyl group of 
the substrate. This forms the unstable hemi-acetal, which then rearranges causing the 
demethylation, forming formaldehyde. 
 
 
1.2.3 Terminal Olefin Reaction 
 Substrates involving terminal olefins can go through a slightly different 
mechanistic pathway. Terminal olefins are involved in a nonconcerted olefin epoxidation 
pathway6. Through this reaction, terminal olefins are not only oxidized to the 
corresponding epoxides but also involved in alkylating one of the prosthetic heme 
nitrogen atoms, as seen in figure 4. Mechanistically, since this is a nonconcerted reaction, 
the epoxide does not alkylate the heme group. The heme alkylation occurs before the 
formation of the epoxide metabolite, resulting deactivation/inhibition of the P450. 
!
! 7 
 
Figure 4. Terminal Olefin Reaction. The reaction involves the alkylation of nitrogen 
from the heme group of the P450 enzyme during the oxidation of the terminal olefin. 
 
 
1.2.4 Benzene Hydroxylation Reaction 
 Aromatic compounds are common substrates that are catalyzed by CYP P450s. 
As shown in figure 5, the mechanism involves the removal of hydrogen from a benzene 
ring. Upon being oxidized via the P450 catalytic pathway, an epoxide forms. An NIH 
shift is observed, which allows the aromaticity to be restored and the benzene to be 
hydroxylated to give a final product of phenol. 
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Figure 5. Benzene Hydroxylation Reaction. The arene oxide is formed from the 
metabolism of benzene via the catalytic cycle; from this an NIH shift is observed which 
eventually leads to a hydroxylation of the benzene to a phenol7.  
 
 
1.3.0 Inhibition of Cytochrome P450s 
 It is vital to understand the interactions of natural products and CYP P450 
isozymes. Natural products are being used to treat illnesses in an increasing number by 
people in the United States8. For this it is important to understand how these natural 
products interact with CYP P450 enzymes. Natural products consist of many small 
molecules that can influence enzymatic activity drastically. To understand these affects it 
is important to determine the mode of inhibition from these chemical compounds 
involving CYP P450s.  
 The Michaelis-Menten model is widely used to determine enzyme activities with 
CYP P450s. As seen in figure 6, the Michaelis-Menten model illustrates the relationship 
between enzyme and substrate concentration. The Vmax represents the maximum rate of 
product formation after the saturation of all available enzymes by the substrate. The other 
variable that can be determined from this model is Km, which represents ½ Vmax. The Km 
indicates where 50% of the substrate is bound to the enzyme. With the introduction of 
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inhibitor this model can be used to describe the nature of the interaction between P450 
and molecules that inhibit the enzyme. 
 Enzymatic activity can be altered in the presence of inhibitors. An inhibitor 
consists of any molecule that restricts the enzyme from its function. As stated before 
Cytochrome P450s maybe involved in generating ROS’s, with the presence of inhibitors 
with certain xenobiotic interactions this process can be limited or in some case 
completely neutralized. The focus of this study is to focus on compounds found in natural 
products and their inhibitory affects on CYP P450s. There are two types of inhibitors, 
irreversible and reversible, and they are classified by their mode of binding to the 
enzyme. 
 Reversible inhibitors compete with the substrate and bind to the active site, thus 
preventing the substrate from binding to the active site. The effects of a reversible 
inhibitor on the enzyme only last as long as it’s present in the system9. Once the inhibitor 
is removed from the environment normal activity will resume. The strength of these 
inhibitors is determined by there binding affinities. Inhibitors bind to the active site via 
interactions with amino acids within the active site or by hydrogen binding10. 
 Irreversible inhibitors bind to the enzyme covalently. These types of inhibitors 
chemically alter the enzyme shape in such a way that it permanently inactivates the 
enzyme. Such inhibitors are sometimes referred to as “suicide inhibitors”. 
Mechanistically irreversible inhibitors mode of action on CYP P450s usually involves 
chemical modification of the heme cofactor, such as the terminal olefin example 
described above11. 
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Figure 6. Michaelis-Menten Schematic. The Michaelis-Menten model, showing the 
relationship between reaction rate and substrate concentration. The Vmax represents the 
maximum rate at which product is formed, and Km represents ½ Vmax. 
 
1.4.0 Role of CYP 2E1 in Oxidative Stress 
 Oxidative stress results from the increase of intracellular prooxidant species such 
as hydrogen peroxide, hydroxyl radicals, and superoxide anion radical1. Elevated levels 
of these molecules can go onto cause mitochondrial damage, DNA modifications, lipid 
peroxidation, elevated cytokine production, and eventually cell death. In mammals, ROS 
can have serious implications such as Alzheimer’s disease, atherosclerosis, cancer, 
diabetes, chronic obstructive pulmonary disease, and neurological disorders12. 
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 Oxidative stress is believed to be one of the fundamental reasons why the process 
of aging occurs13. CYP2E1, as mentioned before is involved in generating high levels of 
ROS in vitro and in vivo. During the catalytic cycle, CYP450s use a hydride from 
NADPH to reduce oxygen, which leads to the production of hydrogen peroxide and 
superoxide anion radical. When the process is uncoupled from the catalytic cycle, this 
causes the release of these ROS. Studies have clearly shown that in the absence of 
substrate, the 2E1 isoform is proficient in generating ROS through this route14,15. This 
occurrence is called futile cycling. It occurs because P450-derived NADPH oxidase 
activity is independent of exogenous xenobiotic substrates17. CYP2E1 expression is said 
to be elevated with the induction of non-alcoholic steatohepatitis (NASH), which results 
in oxidative stress9. ROS that are produced as a result of CYP2E1 can produce lipid 
peroxides from polyunsaturated fatty acids, and these react with other cellular 
macromolecules causing cell toxicity and death1.  
 
1.4.1 Cytochrome P450 2E1 
 A goal of this study is to identify natural products that selectively inhibit 
CYP2E1. In particular the study focuses on commonly used essential oils. CYP2E1 is 
mainly located in the liver but is also found in areas such as the lungs, brain, and other 
tissue18. Studies have shown that CYP2E1 levels are elevated in the liver when alcohol 
levels are high. This could possibly be an explanation to why alcoholics develop liver 
disease19. The enzyme is involved in inducing oxidative stress that can potentially be 
extremely detrimental to human health. CYP2E1 is found to metabolize p-nitrophenol 
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into nitrocatechol with a high binding affinity. The active site of CYP2E1 is relatively 
hydrophobic and small compared to other CYP P450 enzymes. It is reported that 
CYP2E1 is one of the smallest active sites that exists in the CYP450 family. The overall 
size of the active is 190 angstroms, which explains why the substrates and inhibitors for 
CYP2E1 are small in molecular weights20. CYP2E1 has nonpolar phenylalanine residues 
that make upper part of the active site, which explains why it interacts with aromatic 
compounds such as p-nitrophenol. In figure 7, the reaction of CYP2E1 oxidizing p-
nitrophenol to nitrocatechol is represented. The identification of inhibitors to inhibit 
CYP2E1 is important because of its ability to induce oxidative stress. In alcohols such as 
ethanol, CYP2E1 plays a vital role in metabolizing it to a more reactive and toxic product 
acetaldehyde. Studies have shown that if CYP2E1 levels decrease then alcohol induced 
liver damage also decreases6. Compounds such as diallyl sulfide (DAS), phenethyl 
isothiocyanate (PIC), and chlormethizole have been shown to inhibit CYP2E1, and have 
been shown to reduce the damaging effects of 2E1-dependent metabolism in-vivo21.  
From this it can be concluded that natural products can be effective inhibitors of 
CYP2E1, which may prevent oxidative stress from occurring under certain conditions. 
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Figure 7. Reaction of CYP2E1 with p-Nitrophenol. The reaction causes the p-
nitrophenol to be oxidized to nitrocatechol. 
 
 
1.5.0 Cytochrome P450 2A6 
 Cytochrome P450 2A6 (CYP2A6) is the most abundant of the cytochrome P450 
2A family located in the human body22. It is expressed in moderate levels in hepatic cells, 
localized within the endoplasmic reticulum. CYP2A6 is not a major drug-metabolizing 
enzyme, studies show that it metabolizes less than 5% of all drugs6. One of the major 
roles of CYP2A6 is detoxification of nicotine in the human body. CYP2A6 studies tend 
to focus on its involvement in the metabolism of xenobiotics and potential production of 
carcinogenic intermediates. CYP2A6 metabolizes coumarin to 7-hydroxycoumarin, as 
shown in figure 8. Since it is the only enzyme that carries out this reaction, it is ideal to 
use it as a substrate for CYP2A6. The active site of CYP2A6, like CYP2E1, is small and 
hydrophobic23. For this compactness, it only allows small planer and hydrophobic 
substrates to enter, making coumarin an ideal choice. When coumarin is in the active site, 
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the carbonyl oxygen hydrogen bonds with the Asn29723. Asn297 interacts with the 
coumarin and holds it in such away that it can be oxidized. Another significant 
interaction arises with the presence of Phe107 in the active site; this amino acid residue 
interacts with the aromatic aspect of the substrate. These interactions show why coumarin 
is an ideal substrate for CYP2A6. 
 
Figure 8. Reaction of CYP2A6 with Coumarin. The reaction causes coumarin to be 
catalyzed over to 7-hydroxycoumarin. 
 
 
1.5.1 CYP2A6 Role in Metabolism 
Harmful substances that are located within cigarettes are also bioactived by 
CYP2A6, which are potentially cancer-causing agents24. Thus inhibition of this isoform 
may also result in a protective effect under specific environmental conditions. CYP2A6 is 
involved in the metabolism of nicotine that enters the body, to cotinine25. Inhibited 
CYP2A6 could potentially be used as an approach for smoking cessation23. As mentioned 
before, CYP2A6 is known to bioactivate chemical compounds into cancer causing ones, 
nitrosamines being a key example of this activation. It was found that patients that had an 
absence of the CYP2A6 enzyme had a lower risk of lung cancer when compared to the 
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ones that had the enzyme present26. Therefore inhibition of this enzyme may also reduce 
the risks of lung cancer. 
 
1.6.0 Essential Oils 
 Essential oils have proven their usefulness throughout human history for multiple 
purposes, such as aromatherapy, medicinal, and for culinary uses. Essential oils that were 
used in this study are Artemisia dracunculus (Tarragon) and Ocimum basilicum (Basil). 
While these oils contain a vast array of constituents, they both have a significant presence 
of estragole (1-allyl-4-methoxybenzene). 
 
1.7.0 Objective Statement 
 The purpose of this study is to determine the activity of CYP2E1 and CYP2A6; 
an in vitro assay was developed to measure the activity of these enzymes using hepatic 
microsomes from rabbits, rats, and humans. The substrate, p-nitrophenol was selected for 
CYP2E1 and coumarin for CYP2A6. These substrates were chosen because of there 
specificity to binding to the enzyme. The strategy employed was to screen a series of 
essential oils for inhibition of these enzymes.  
 Tarragon and basil were selected because of their inhibitory affects on enzymatic 
activity. Studies will include identifying which component in the oil is/are responsible for 
the inhibition, and what type of inhibition is occurring (irreversible or reversible), and 
from this a mechanism will be proposed of how this potential inactivation of the enzyme 
is transpiring. 
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CHAPTER II 
EXPERIMENTAL 
 
 
2.1.0 Preparation of Reagents 
 
2.1.1 Phosphate Buffer and NADPH 
 Potassium phosphate buffer was prepared by mixing monobasic potassium 
phosphate and dibasic potassium phosphate, both of which were purchased from Carolina 
Biological Supply Company. A 1 M stock solution at pH 7.4 was used for all assays 
involved in this project. NADPH was purchased from Research Products International. It 
was then diluted with Nano-pure water and partitioned into 10 mM stock solution 
aliquots. These aliquots were stored in a freezer at -80°C. 
 
2.1.2 Preparation of Rabbit Liver Microsomes 
 Rabbit liver microsomes were used in this study to obtain a comparative analysis 
(human and rat being other hepatic microsomes) across species. Rabbit liver microsomes 
were generated in lab. The rabbit liver was first washed in 0.05 M potassium phosphate 
buffer at pH 7.4, which also comprised of 0.1mM of EDTA. Rabbit liver and buffer 
solution was then blended to obtain a homogenized mixture Next the liver was 
centrifuged at 5,000 rpm for 10 minutes. The pellets were then discarded and the 
supernatant was centrifuged at 37,000 x g for 1 hour. The microsomes were then  
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homogenized in a solution of potassium phosphate buffer at pH 7.4. Lastly, the 
microsomes were put in 200 µL aliquots and stored in the -80°C freezer for usage. 
 
2.1.3 Preparation of Rat Liver Microsomes 
 Rat liver microsomes were also prepared in lab (as part of the comparative 
analysis across species). The rat liver was first rinsed in a solution that comprised of 
100mM potassium phosphate buffer at pH 7.4, 0.1 mM EDTA, 20% glycerol, 3.3 mM 
MgCl2. Then the liver and buffer were put into a blender to mix and obtain a 
homogenized mixture. The blended mixture was then centrifuged at 5,000 rpm for 10 
minutes. The supernatant was then again centrifuged but this time at 25,000 x g for 1 
hour. Upon the completion of this, the supernatant was removed and the pellets were 
homogenized in potassium phosphate buffer at pH 7.4. Lastly, the microsomes were put 
in 50 µL aliquots and stored in the -80°C freezer for usage. 
 
2.1.4 Human Liver Microsomes 
 Human liver microsomes were purchased from Molecular Toxicology Inc. They 
were put in 50 µL aliquots and stored in -80°C freezer for usage.  
 
2.1.5 Preparation of p-Nitrophenol 
 The reagent p-nitrophenol (p-NP) was purchased from Sigma-Aldrich. 13.9 mg of 
p-NP was weighed out and dissolved in 10 mL of deionized water to give 10 mM stock 
solution. This solution was then diluted 1:10, to give a final concentration of 1 mM stock 
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solution of p-NP, which was used as a substrate for all assays that involved CYP2E1 
enzyme. 
 
2.1.6 Preparation of Coumarin 
 The reagent Coumarin was purchased from Sigma-Aldrich. 15 mg of the 
Coumarin was weighed and dissolved in 10 mL methanol solution; this is done because 
of Coumarins low solubility in water, this gives a 0.01 M stock solution. Then this 
solution was diluted 100X to give a final concentration of 100 µM, which was used in all 
assays involving CYP2A6. 
 
2.1.7 Preparation of Nash Reagent 
 The Nash reagent was used to identify the formation of possible formaldehyde 
from the metabolism of estragole by CYP2E1 and CYP2A6. The reagent was prepared by 
mixing 15g of sodium acetate, 200 µL of 2,4-pentandione, and 400 µL glacial acetic acid 
to give a total volume of 50 mL. The solution was vortexed for 5 minutes and stored in a 
low light environment in the 4°C refrigerator. 
 
2.2.0 CYP P450 Assay Development 
 The study involves measuring product formation by measuring different 
parameters such as microsomal and substrate concentration, time, and inhibitor affects on 
CYP2E1 and CYP2A6. Inhibition studies were carried out to determine the inhibitory 
effects of tarragon and basil on the enzyme. These two oils have a common substituent in 
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high concentrations named estragole, which was also separately tested to study the 
kinetic effects on the enzymes. 
 
2.3.0 Initial Screening Assay for CYP2E1 
 CYP2E1 was tested with various essential oils to determine their inhibitory 
effects on the enzyme. Primarily the goal was to identify essential oils with strong 
inhibitory potency towards the enzyme. For CYP2E1, p-nitrophenol was picked as a 
substrate for the enzyme, which produces nitrocatechol (as seen in figure 7). Essential 
oils were diluted 5 µL in a 100 mL of deionized water to make the stock solution. In a 
1.5mL centrifuge tube a reaction mixture containing 0.1M potassium phosphate buffer 
(pH 7.4), liver microsomes (from rat ~15.3 µg/mL, rabbit, and human-23.3 µg/mL), 1mM 
p-nitrophenol, and various concentrations of the oils were prepared. Deionized water was 
added to bring the final volume up to 200 µL per sample. The reaction was vortexed and 
then initiated with the addition of 1mM NADPH and incubated for 30 minutes at 370C. 
After 30 minutes, the reaction was quenched using 6% perchloric acid, vortexed, and then 
put into an ice bath for approximately 6-8 min. The reaction was taken out of the ice bath, 
and centrifuged for 8 minutes at 14,000 g to remove the precipitate. Then the supernatant 
was transferred into an HPLC vial for HPLC analysis. 
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2.3.1 HPLC Analysis 
 The reactions involving p-nitrophenol oxidation were examined using HPLC 
(high-performance liquid chromatography). The analysis was conducted using a 
Shimadzu Automated liquid Chromatography system with UV detection at 340nm. The 
system was programed to inject 75 µL of each sample onto a C18 column (4.6x150mm) 
with a flow rate of 1.5 mL/min. The mobile phase used for this method contained 40% 
acetonitrile, 60% deionized water with 0.1% trifluoroacetic acid. The nitrocatechol peak 
from each reaction was integrated to give peak areas, where the areas under the curves 
represent the relative activity of the CYP2E1 enzyme found in rat, rabbit, and human. 
 
2.3.2 CYP2E1-Determination of KI 
 Enzyme kinetic studies were carried out using hepatic microsomes from human, 
rat, and rabbit with tarragon, basil, and estragole. The reaction mixture contained 0.1 M 
potassium phosphate buffer, pH 7.4, varying concentrations of substrate, p-NP, ranging 
from 10 µM-100 µM, hepatic microsomes, a specified concentration of inhibitor which 
ranged from 0-23.00 µg/mL, and nanopure water was added to bring the reaction volume 
up to 200 µL. After all components of the reaction were added, the vials were vortexed, 
the 0.5 mM NADPH was added to the reaction mixture and placed inside an incubator at 
370C for 30 minutes. After 30 minutes, the reactions were quenched with 6% perchloric 
acid and placed in an ice bath for 8 minutes. Samples were then centrifuged for 8 minutes 
at 14,000 g, to remove the precipitate. 200 µL of the supernatant was then placed inside 
of an HPLC vial insert for HPLC analysis. 
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 An important tool for studying enzyme kinetics is the Michaelis-Menten model. 
This model is used to determine the apparent KI for each inhibitor. KI was found by 
plotting V vs. [S] at a range of increasing concentration of the substrate, p-NP, in both the 
presence and absence of the inhibitor. The inhibitor concentration was chosen from 
screening experiments carried out on the oils where  ~50% inhibition of CYP2E1 was 
observed. The Slide Write Plus (by Advanced Graphics Software, Inc.) program was used 
to plot the relative activity vs. concentration of p-NP. The Michaelis-Menten equation, as 
seen in equation 1, was used to determine the maximum velocity without inhibitor 
present, Vmax, with inhibitor present, V max app. The substrate concentration at which the 
enzymatic activity is ½ the Vmax, represented by Km, and the substrate concentration with 
the presence of inhibitor when the enzyme is ½ the Vmax app, which is represented by 
Kmapp. 
 
Vo= Vmax* [S] 
        Km+ [S] 
 
Equation 1. The Michaelis-Menten Equation. 
 
 
Using Equation 2, the KI was calculated using the concentration of inhibitor. 
 
 
Vmax/Vmaxapp = 1+ [I]/Ki 
 
Equation 2. Equation for Calculating KI for Non-Competitive Inhibition. 
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2.3.3 Two Stage-Reversibility Studies Assay 
With preliminary studies showing definite inhibition of CYP2E1 using tarragon 
and basil, the next phase was to look at how the enzyme was inhibited. To determine if 
the inhibition was irreversible or reversible, a method using two stages was applied. The 
experiment was done with multiple parameters (altering the components in stage I). 
Multiple parameters were constructed by changing the volume of microsomes, changing 
the concentration of inhibitor, and changing pre-incubation time (stage I) and incubation 
time (stage II).  
Table 1-A, 1-B, show the parameters used for each stage I experiment. 20 µL 
from the stage I vials was transferred to stage II of the experiment. In stage II, the vials 
had 20 µL from each respective vial from stage I, 20 µL of potassium phosphate buffer, 
10 µL of p-nitrophenol, 20 µL of NADPH, and 130 µL of deionized water. Final volume 
of the reaction in stage II was 200 µL. In the vial where D was transferred, inhibitor (1-3 
µL depending upon reaction conditions) was added into the stage II reaction vial.  
Vial A in this experiment represented reaction conditions which would allow the 
inhibitor to damage the P450, if the reaction is irreversible then there would be no/or less 
remaining activity toward the substrate when the 20 µL is transferred to stage II, but if its 
reversible then there would be full activity with the substrate in stage II to the P450. 
NADPH is also added in vial A to see if the inhibition is dependent upon NADPH. In vial 
B, everything is the same as A, except there is no addition of NADPH. Vial C represents 
a control, with just microsomes and buffer, when transferred over to stage II part of the 
reaction, the substrate should bind to the P450 to give full activity (which then can be 
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compared with Vial A and B). Vial D, is the same as Vial C, but in stage II part of the 
reaction, the inhibitor is added before 20 µL of Vial D is transferred. This is to ensure that 
any inhibitor carried over into stage II does not inhibit the reaction. 
From Table 1-A, two reaction conditions were setup. The first reaction involved 
taking the vials prepared in stage I and leaving them out at room temperature for 30 
minutes then transferring 20 µL to stage II reaction, where it was then incubated at 370C 
for 30 minutes. The reaction was then quenched with 200 µL of 6% perchloric acid. The 
second reaction condition involved taking the vials prepared in stage I and leaving them 
out at room temperature for 10 minutes and then transferring 20 µL to stage II reaction, 
where it was then incubated at 370C for 30 minutes. The reaction was then quenched with 
200 µL of 6% perchloric acid. The results for both of these experiments can be seen in 
figure 18A-B. 
From Table 1-B, two reaction conditions were setup. The first reaction (Figure 
19A-B) involved taking the vials prepared in stage I and leaving them out at room 
temperature for 12 minutes then transferring 20 µL to stage II reaction, where it was then 
incubated at 370C for 30 minutes. The reaction was then quenched with 200 µL of 6% 
perchloric acid. The second reaction condition involved taking the vials prepared in stage 
I and leaving them out at room temperature for 36 minutes, then transferring 20 µL to 
stage II reaction, where it was then incubated at 370C for 45 minutes. The reaction was 
then quenched with 200 µL of 6% perchloric acid. The reason the reaction duration was 
increased was because it was believed that the kinetic rate of the reaction might be slow 
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thus increasing the time might enhance any irreversible type inhibition. The overall 
reaction setup can be seen in Figure 9. 
 
Table 1-A. Two-Step Reversibility Study-First Parameter. This was used to determine 
if the reaction is irreversible or reversible. The inhibitor used was estragole: initially 5 µL 
of oil was dissolved in a 100mL of deionized water to make a stock solution. The 
concentration of inhibitor used was 9.33ug/mL. 
 
Vial A: Vial B: Vial C: Vial D: 
15 µL of human 
liver microsomes 
15 µL of human 
liver microsomes 
15 µL of human 
liver microsomes 
15 µL of human 
liver microsomes 
5 µL of potassium 
phosphate buffer 
5 µL of potassium 
phosphate buffer 
5 µL of Buffer 5 µL of Buffer 
5 µL of NADPH 5 µL of Deionized 
Water 
15 µL of Deionized 
Water 
15 µL of Deionized 
Water 
10 µL of Inhibitor 10 µL of Inhibitor - - 
 
Table 1-B. Two-Step Reversibility Study-Second Parameter. This was used to 
determine if the reaction is irreversible or reversible. The volume of human liver 
microsomes was tripled from 15 µL to 45 µL in the initial incubation. The inhibitor 
(estragole) concentration was tripled, 15 µL of inhibitor was diluted in 100mL of 
deionized water. Thus the concentration of inhibitor used was 21.2ug/mL. 
 
Vial A: Vial B: Vial C: Vial D: 
45 µL of human 
liver microsomes 
45 µL of human 
liver microsomes 
45 µL of human 
liver microsomes 
45 µL of human 
liver microsomes 
15 µL of potassium 
phosphate buffer 
15 µL of potassium 
phosphate buffer 
15 µL of Buffer 15 µL of Buffer 
15 µL of NADPH 15 µL of Deionized 
Water 
25 µL of deionized 
water 
25 µL of deionized 
water 
10 µL of Inhibitor 10 µL of Inhibitor - - 
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Figure 9. Two-Stage Reversibility Study Setup. 
 
 
2.3.4 Time Dependent Studies Assay-CYP2E1 
 Time dependent studies were done to determine the affects of the essential oils on 
CYP2E1 over time. This was also another method used to determine if the reaction was 
reversible or irreversible. The reaction conditions for this assay involved hepatic 
microsomes (human, rat, and rabbit), 0.1 M Potassium Phosphate buffer, pH 7.4, 50 µM 
of substrate, p-NP, 5.8 µg/mL of tarragon and basil, for estragole 40 µM were used (these 
concentration was used because this is where the enzyme is ~50% inhibited), also a 
control was run without inhibitors, and 115 µL of nanopure water was added to a vial. 0.5 
!
! 26 
mM NADPH was added to the initiate the reaction, also bringing the reaction volume to 
200 µL. The reaction was quenched with 6% perchloric acid at 10, 20, 40, 60, and 80 
minutes and then placed in an ice bath for 8 minutes. Samples were then centrifuged for 8 
minutes at 14,000 g, to remove the precipitate. 200 µL of the supernatant was then placed 
in an HPLC vial insert for HPLC analysis. 
 
2.4.0 Initial Screening Assay for CYP2A6 
 CYP2A6 was tested with various essential oils to determine their inhibitory 
effects on the enzyme. Primarily the goal was to identify essential oils with strong 
inhibitory potency towards the enzyme. For CYP2A6, coumarin was picked as a substrate 
for the enzyme, which produces 7-hydroxycoumarin (as seen in figure 8). Essential oils 
were diluted 5 µL in a 100 mL of deionized water to make the stock solution. In a 1.5mL 
centrifuge tube a reaction mixture containing 0.1M potassium phosphate buffer (pH 7.4), 
20 µL liver microsomes (from rat, rabbit, and human), 50 µM 1mM p-nitrophenol, and 
various amounts of each oil was prepared. Deionized water was added to bring the final 
volume up to 200 µL per sample. The reaction was vortexed and then initiated with the 
addition of 0.5 mM NADPH and incubated for 30 minutes at 370C. After 30 minutes, the 
reaction was quenched using 6% perchloric acid, vortexed, and then put into an ice bath 
for 8 min. The reaction was taken out of the ice bath, and centrifuged for 8 minutes at 
14,000 g to remove the precipitate. Then the supernatant was transferred into an HPLC 
vial for HPLC analysis 
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2.4.1 HPLC Analysis 
 The reactions involving coumarin oxidation were examined using HPLC (high-
performance liquid chromatography). The analysis was conducted using a Shimadzu 
Automated liquid Chromatography system with UV detection at 320nm. The system was 
programed to inject 75 µL of each sample onto a C18 column (4.6x150mm) with a flow 
rate of 1.0 mL/min. The mobile phase used for this method contained 40% acetonitrile, 
60% deionized water with 0.1% trifluoroacetic acid in both reagents. The 7-
hydroxycoumarin peaks from each reaction was integrated to give peak areas, where the 
areas under the curves represent the relative activity of the CYP2A6 enzyme found in 
rabbit and human livers. 
 
2.4.2 CYP2A6-Determination of KI 
 Hepatic microsomes from human and rabbit with tarragon, basil, and there major 
constituent estragole were used to carry out enzyme kinetic studies. The reaction mixture 
contained 0.1 M potassium phosphate buffer, pH 7.4, varying concentration of substrate, 
coumarin, ranging from 1 µM-10 µM, hepatic microsomes, a specified concentration of 
inhibitor that ranged from 0-23.00 µg/mL, and nanopure water was added to bring the 
reaction volume up to 200 µL. After all components of the reaction were added, the vials 
were vortexed, 0.5 mM NADPH was added to the reaction mixture and placed inside an 
incubator at 370C for 30 minutes. After 30 minutes, the reactions were quenched with 6% 
perchloric acid and placed in an ice bath for 8 minutes. Samples were then centrifuged for 
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8 minutes at 14,000 g, to remove the precipitate. 200 µL of the supernatant was then 
placed inside of an HPLC vial insert for HPLC analysis.  
The Michaelis-Menten model was used to study the activity of the enzyme. 
Equation 1 was used to determine the Vmax, Vmaxapp, Km, and Kmapp. Michaelis-Menten 
model was used to determine the type of inhibition and the potency of the inhibitor on the 
enzyme. The KI was calculated for a non-competitive inhibitor using Equation 2. KI was 
calculated for both the presence and absence of inhibitor in the reaction. 
 
2.4.3 Time Dependent Studies Assay-CYP2A6 
 To determine the mode of inhibition, reversible or irreversible, time dependent 
studies were done with tarragon, basil, and estragole on CYP2A6. The reaction 
conditions for this assay involved hepatic microsomes (human, rat, and rabbit), 0.1 M 
Potassium Phosphate buffer, pH 7.4, 5.0 µM coumarin, 5.8 µg/mL of tarragon and basil, 
for estragole 40 µM were used (these concentration were used because this is where the 
enzyme is ~50% inhibited), also a control was run without inhibitors, and 115 µL of 
nanopure water was added to a vial. 0.5 mM NADPH was added to the initiate the 
reaction, also bringing the reaction volume to 200 µL. The reaction was quenched with 
6% perchloric acid at 10, 20, 40, 60, and 80 minutes and then placed in an ice bath for 8 
minutes. Samples were then centrifuged for 8 minutes at 14,000 g, to remove the 
precipitate. 200 µL of the supernatant was then placed in an HPLC vial insert for HPLC 
analysis. 
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2.5.0 Nash Assay 
 The Nash Assay is a method used to measure the formation of formaldehyde. In 
this study the Nash assay was used with CYP2E1 and CYP2A6 to determine if they were 
metabolizing estragole to form the formaldehyde product via demethylation. The Nash 
reagent includes ammonium acetate and 2,4-pentandedione, and acetic acid. The reagent 
reacts with the formaldehyde to give 3,5-diacetyl-2,6-dihydrolutidine, which gives a 
yellow color. The yellow color can be quantified to determine how much formaldehyde 
forms. The appearance of the yellow color in this study would indicate that the P450 has 
carried out the O-Demethylation reaction (figure 3). 
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CHAPTER III 
RESULTS AND DISCUSSION 
 
 
3.1.0 CYP2E1 Enzyme Activity 
 Several parameters were tested in order to optimize the bioassay for testing 
activity involving CYP2E1. This process involved testing varying concentration of 
enzyme, substrate concentration, and incubation time. Rat, rabbit, and human liver 
microsomes were tested for their enzymatic activity. The assays were prepared using 
similar conditions as mentioned previously with equivalent concentrations of potassium 
phosphate buffer, substrate (PNP), and NADPH, but with no inhibitor. Figure 10 shows 
how varying concentration of microsomes were tested with the substrate, p-nitrophenol, 
to show its effects on the formation of nitrocatechol. As expected, increase in microsomal 
concentration resulted in a corresponding linear increase of product formation in the 30-
minute reaction. From this it was determined that 20 µL of the rat liver microsomes, 20 
µL of rabbit Liver, and 5 µL of the human liver microsomes produced sufficient activity 
for use in this study. 
 CYP2E1 microsomes were then tested to determine the linearity over time. 
Activity should increase in a linear fashion with the increase of reaction time, assuming 
no inactivation occurred. As shown in figure 11, the effects of reaction time on CYP2E1 
activity again followed a predictable linear dependence out to nearly 1-hour incubation 
time. From this it was determined that an incubation time of 30 minutes was appropriate.
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Figure 10. Results for Variation in Microsomal Concentration-CYP2E1. From this it 
was determined the amount of microsomes used for each species for their respective 
bioassay. 
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!
Figure 11. Results for Variation in Incubation Time-CYP2E1. From this it was 
determined that the appropriate time for the bioassays will be 30 minutes. 
 
 
 CYP2E1 was tested using different concentrations of substrates to determine the 
Michaelis-Menten enzyme kinetic parameters. Through this analysis it was determined 
that the Km value for the substrate to be approximately 50 µM (data not shown). 
 
3.1.1 Inhibition of CYP2E1 by Essential Oils 
 CYP2E1 was tested with various essential oils to determine their inhibitory 
effects on the enzyme activity. Primarily the goal was to identify essential oils with 
strong inhibitory potency toward CYP2E1. Figure 12, shows several of the essential oils 
that were tested against the 2E1 enzyme. The data ranged from barely any inhibition to 
very potent inhibition, as seen with tarragon. Tarragon was selected out of the five 
essential oils that were tested because it demonstrated the greatest level of inhibition. The 
!
! 33 
main constituent found in tarragon is estragole; from this it was proposed that estragole 
might be the cause of inhibition of activity of CYP2E1. 
 
 
 
Figure 12. Screening Data for Essential Oils Inhibitory Affect on CYP2E1. Showing 
data for duplicates for each concentration of oil.  
 
 
According to literature reports, basil oil also has a relatively high concentration of 
estragole present within it. From this information basil oil was also added to the project to 
determine its inhibitory effects on CYP2E1. Gas Chromatography Mass spectrometry 
(GCMS) analysis was done on both oils to confirm the presence of estragole, as seen in 
figure 13. Both oils along with pure estragole were tested with rat, rabbit, and human 
liver microsomes to determine their inhibitory effects on the P450 enzymes of each 
species. 
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A. 
 
B. 
 
 
Figure 13. GCMS Spectra Analysis of Tarragon and Basil. Chromatogram confirming 
the presence of estragole in both tarragon and basil Oil. Peak that appears at 
approximately 6.95 minutes is the estragole peak (estragole represented by the color blue, 
tarragon’s estragole peak is represented by the color black, and basil’s by the color pink), 
panel A shows the overall chromatogram and panel B shows a zoomed version of it. 
 
 
3.1.2 Dose Response Studies 
Initial screening experiments show that the CYP2E1 enzyme is being inhibited 
with increasing concentration of the oils. Both essential oils and estragole were initially 
prepared by diluting 5!µL pure oil (in the case of estragole, pure compound) into 100 mL 
of deionized water. Each of the oils and estragole were included in a reaction that had 50 
µM p-nitrophenol. The concentration of the oils and estragole ranged from 0.0 µg/mL to 
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23.00 µg/mL. Figure 14A-C, shows the percent activity of CYP2E1 remaining with the 
addition of varying concentration of inhibitor.  Microsomes from all three species were 
used. In all three species, the basil oil assays required a higher concentration of inhibitor 
for the activity to decrease by over 50%; this could possibly be explained by the lower 
concentration of estragole present in basil oil. The tarragon oil has a higher concentration 
of estragole present, thus the data in figure 14A-C appear to support this idea (estragole is 
the inhibitory constituent in both basil and tarragon oil). The assay that had estragole and 
tarragon with the human and rabbit liver microsomes had a decrease in activity over 
50% with the addition of 64µM and 9.2µg/mL of inhibitor, respectively.  Human and 
rabbit liver microsomes with basil oil required 13.8ug/mL to lose over 50% of its initial 
activity. The assay with estragole and tarragon that had rat liver microsomes had a 
decrease in activity over 50% with the addition of only 32µM and 4.6µg/mL of inhibitor 
respectively. Basil oil with the rat liver microsomes required 9.2µg/mL to lose over 50% 
of its initial activity (possibly due to the lower concentration of estragole). In general, the 
rat liver microsomes appeared to be more sensitive to the inhibitors compared with the 
human and rabbit. Table 2 shows the IC50 values calculated for each inhibitor with all 3 
species.  It should be noted that the concentrations of estragole of 64 mM and 32 mM 
correspond to 9.2 µg/mL and 4.6 µg/mL, respectively. Given that the overall content of 
the tarragon is >80% estragole, this is fully consistent with our assertion that estragole is 
the active component of the tarragon oil. 
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Table 2. IC50%Values%for Inhibitors with CYP2E1.!
 
 Tarragon Basil Estragole 
Human Liver 
CYP2E1- IC50 
9.2!µg/mL 13.8!µg/mL 64!µM 
Rabbit Liver 
CYP2E1-%IC50 
9.2!µg/mL 13.8!µg/mL 64!µM 
Rat Liver 
CYP2E1-%IC50 
4.6!µg/mL 9.2!µg/mL 32!µM 
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14-A. 
 
 
!
 
Figure%143A.%Dose Response Studies with CYP2E1-Rabbit.!
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14-B. 
 
!
!
!
Figure%143B.%Dose Response Studies with CYP2E1-Rat.!
!
!
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143C.!
!
!
!
!
Figure%143C.%Dose Response Studies with CYP2E1-Human.%!
!
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3.1.3 Michaelis-Menten Studies-CYP2E1 
 The Michaelis-Menten model of enzyme kinetic and inhibition was used to obtain 
a more accurate representation of the inhibitory effects of the essential oils on CYP2E1. 
The kinetics study was carried out with different concentrations of the substrate, p-NP, 
ranging from 10 µM-100 µM in the presence and absence of the inhibitor. These 
reactions were carried out in duplicates to confirm the results were reproducible. The 
concentration of inhibitors used was determined based on previous studies carried out 
where the enzyme inhibition of ~50% was observed. Human, rabbit, and rat liver 
microsomes were used to generate Michaelis-Menten graphs. When compounds inhibit 
an enzyme there can be a change in the Vmax and/or Km of the substrate reaction. From 
determining the Kmapp and Vmaxapp the mode of inhibition by the inhibitor can be 
determined.  Determining the dissociation constant, KI, is important because it defines the 
amount of inhibitor needed to induce inhibition of the enzyme, and is a general measure 
of the potency of the inhibitor. 
Figure 15 shows the Michaelis-Menten graph for the oxidation of p-nitrophenol 
by human liver microsomes in the presence and absence of inhibitor. The Vmax for the 
reaction with no inhibitor was 468.73 activity units (defined as the peak area for the 
product formed in a 30 min reaction). When tarragon, basil, and estragole were added to 
the reaction, there was a drastic decrease in Vmaxapp. The Vmaxapp for the inhibitors were as 
follows: tarragon, 297 AU, basil, 312 AU, and estragole, 168 AU. The Km values for the 
reaction varied only slightly: with no inhibitor in reaction Km: 37, tarragon Km: 60, basil 
Km: 49, and estragole Km:: 47. When Vmax is reduced and Km remains the same, this 
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suggests that the inhibition is non-competitive. Using equation 2, the KI values were 
calculated for each inhibitor, KI values are as followed, tarragon: 10.0 µg/mL, basil: 11.5 
µg/mL, and estragole: 22.4 µM. 
 
 
Figure 15. Michaelis-Menten Plot for CYP2E1-Human Liver. Results for Human 
liver microsomes with the presence and absence of inhibitor. 
 
 
 Michaelis-Menten kinetic studies were carried out with rat liver microsomes with 
the presence and absence of inhibitor, which can be seen in figure 16. Vmax for the 
reaction without the addition of inhibitor was 346 AU. With the addition of tarragon, 
basil, and estragole to the reaction, there was a decrease in Vmaxapp. The Vmaxapp for the 
inhibitors was as follows: tarragon: 283AU, basil: 291 AU, and estragole: 271 AU. The 
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Km values of the reaction stayed in approximately the same range, with no inhibitor in 
reaction the value of Km was: 48 mM, tarragon Km: 52 mM, basil Km: 51 mM , and 
estragole Km: 52 mM. Using equation 2, the KI values were calculated for each inhibitor, 
KI values are as followed, tarragon: 26µg/mL, basil: 30 µg/mL, and estragole: 143 µM. 
With the Vmax changing considerably and the Km remaining reasonably constant, a non-
competitive form of inhibition was inferred. Interestingly, the results from the Michaelis-
Menten analysis suggest that the inhibitor is more potent with human liver CYP2E1 as 
compared to rat.  Although this appears to conflict with the IC50 values reported 
previously, it should be noted that the human 2E1 has a lower Km for the substrate, so 
using the same concentration of substrate for the IC50 determinations could give the 
appearance of a more potent binding to the rat enzyme in those experiments.  As a 
general rule, KI is a more accurate measure of potency than IC50. 
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Figure 16. Michaelis-Menten Plot for CYP2E1-Rat Liver. Results for rat liver 
microsomes with the presence and absence of inhibitor. 
 
 
 Michaelis-Menten kinetic studies were carried out with Rabbit liver CYP2E1 
enzymes. The presence and absence of inhibitor were both studied in order to determine 
the type of inhibition occurring, results for this could be seen in figure 17. The Vmax  for 
the reaction without inhibitor was 94 AU. When the inhibitor was added to the reaction 
there was a decrease in enzymatic activity. The Vmaxapp for the inhibitors was as follows, 
tarragon: 72 AU, basil: 80 AU, and estragole: 69 AU. The Km values of the reaction 
stayed in approximately the same range, with no inhibitor in reaction the value of Km 
was: 48 mM, tarragon Km: 58 mM , basil Km: 56 mM , and estragole Km: 55 mM. Using 
equation 2, the KI values were calculated for each inhibitor, KI values were as follows, 
tarragon: 19 µg/mL, basil: 32µg/mL, and estragole: 108 µM. With the Vmax changing, not 
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as drastically as was seen with the human and rat liver P450, and Km staying constant, 
this suggests non-competitive form of inhibition (for comparative analysis, Vmax, Km, and 
KI values of all 3 species can be found in table 4). Again, here the KI values are higher 
than the ones with human liver, suggesting that the inhibitor is more potent in human 
verses rabbit. Comparing it to rat liver, then the inhibitors are less potent with rat verses 
rabbit.  Again, the higher value of the Km for the substrate observed with the rabbit may 
explain why in the Michaelis-Menten study, the apparent potency of the inhibitors toward 
the rabbit P450 is lower than that of the rat and human enzymes. 
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Figure 17. Michaelis-Menten Plot for CYP2E1-Rabbit Liver. Results for rabbit liver 
microsomes with the presence and absence of the inhibitors. 
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Table 3. Comparative Analysis Showing Values of Vmax, Km, and KI.-CYP2E1. 
 
 
 
3.1.4 Two-Stage Reversibility Study Results 
Research on tarragon and basil showed that their major constituent estragole had a 
terminal olefin present, which may be a suicide substrate for the enzyme through 
irreversible binding and activation at the active site. To determine if the inhibitor was 
reversible or irreversible, a two-stage reversibility study was done. Going by the results 
displayed in Figures 18 A-B and 19 A-B, the reaction appeared to be reversible. This is 
because all the reactions showed almost equal amounts of activity, regardless of how the 
samples were pre-treated the changing of parameters had no overall affects on enzyme 
activity. For example, a mechanism-based inhibitor would be expected to inactivate the 
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enzyme when NADPH and inhibitor were pre-incubated with the enzyme, as was the case 
in figure 18A-B To confirm this, time-dependent studies were carried out using tarragon, 
basil, and estragole. 
 
 
 
Figure 18-A. Reversibility Study-Table 1 A Graph-First Parameter. Graph displays 
the measured activity of each vial from the reversibility study (first reaction as mentioned 
in-text above).  
 
 
 
 
Figure 18-B. Reversibility Study-Table 1 A Graph-Second Parameter. Graph 
displays the measured activity of each vial from the reversibility study (second reaction 
as mentioned in-text above). 
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Figure 19-A. Reversibility Study-Table 1 B Graph-First Parameter. Graph displays 
the measured activity of each vial from the reversibility study (first reaction as mentioned 
in-text above). 
 
 
 
 
Figure 19-B. Reversibility Study-Table 1 B Graph-Second Parameter. Graph 
displays the measured activity of each vial from the reversibility study (second reaction 
as mentioned in-text above). 
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3.1.5 Time-Dependent Study Results 
 Time-dependent studies were carried out to confirm that no irreversible 
inactivation of the enzyme by the essential oils occurred. The reaction was carried out 
over the course of 120 minutes with reactions being quenched at 10, 20, 40, 60, 80, and 
120 minutes. This was done to monitor enzyme inactivation via the inhibitor over a 
course of time. If the inhibitors were irreversible then one should observed activity loss 
by the enzyme at a faster rate in the presence of inhibitor than in the absence. 
Complicating the experiment was the fact that the control reaction also lost activity over 
time, so taking the ratio of the product formed in the absence vs the presence of inhibitor 
was used as a measure of inactivation.  In other words, activity loss would be much more 
rapid in the presence of an irreversible inhibitor. However, if the inhibitors were 
reversible then these ratios should remain relatively constant over duration of the 
reaction. Figure 20A-C shows the results of these studies. Results show that over time 
there is no excess inactivation of the enzyme suggesting that the inhibitor is a reversible 
inhibitor. 
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Figure 20-A. Time-Dependent Studies Graph-CYP2E1-Human Liver. Time-
dependent studies carried out with both essential oils and estragole on human liver 
microsomes. 
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Figure 20-B. Time-Dependent Studies Graph-CYP2E1-Rat Liver. Time-dependent 
studies with rat liver microsomes and the effects of inhibitors tarragon, basil, and 
estragole. 
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Figure 20-C. Time-Dependent Studies Graph-CYP2E1-Rabbit Liver. Time-
dependent studies with rabbit liver microsomes and the essential oils with there major 
constituent estragole. 
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3.2.0 CYP2A6 Enzyme Activity 
 To setup the bioassay involving CYP2A6 several parameters were tested in order 
to determine optimum conditions to carry out the assay. This process involved testing 
liver microsomes from human and rabbit; (rats don’t contain the enzyme CYP2A6), with 
varying concentrations of enzyme, incubation time, and substrate concentration. The 
assay was prepared using conditions mentioned previously. Figure 21 shows how varying 
concentration of microsomes were tested with the substrate, coumarin, to show its effects 
on the formation of 7-hydroxycoumarin. The results were expected, an approximately 
linear increase in product formation was observed with increase in microsomal 
concentration. Based on the test results from these experiments it was determined that 20 
µL of the rabbit liver microsomes and 5 µL of the human liver microsomes were chosen 
for the assays involving CYP2A6. 
 Another component tested for the assay was the affect of time on product 
formation. As reaction time increases this should also increase the amount of product 
form, assuming no inactivation happens. Figure 22 shows an increase in product 
formation with CYP2A6 as reaction duration is increased.  The increase was only linear 
for a short period of time, however, so for inhibition studies, durations of 30 min or less 
were utilized.  
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Figure 21. Results for Variation in Microsomal Concentration-CYP2A6. Effects of 
varying concentration of microsome on formation of 7-hydroxycoumarin. These results 
determined amount of micrsome was used in each respective assay. 
 
 
!
! 55 
 
 
Figure 22. Results for Variation in Incubation Time-CYP2A6. Graph showing the 
effect of time on reaction rate, as time increases so does product formation. From this 
study it was determined that the appropriate time for the bioassay involving CYP2A6 will 
be 30 minutes. 
 
 
3.2.1 Dose Response Studies 
 CYP2A6 has a small hydrophobic active site like its counterpart CYP2E1. Initial 
screening experiment showed inhibition of CYP2A6 with increasing concentration of the 
essential oils. The setup for these dose response study involved taking 5 µL of tarragon 
oil, basil oil, and estragole and diluting it in 100 mL of deionized water. The substrate 
concentration used for this study was 5 µM coumarin. The concentration of the oils 
ranged from 0.0 µg/mL to 23.00 µg/mL, and for estragole it was 0 µM to 160 µM. The 
results of these studies can be seen in figure 23A-B. The inhibitors were tested with both 
human and rabbit liver microsomes. The results showed that the oils and estragole had a 
higher potency toward CYP2A6 as compared to CYP2E1. The basil oil required a higher 
concentration for the activity to be inhibited by 50%, this again is explained by the fact 
!
! 56 
there is a lower concentration of estragole in basil oil, thus requiring a higher 
concentration of it. Tarragon oil has a higher concentration of estragole thus not requiring 
as much to inhibit the enzymatic activity by 50%. Estragole itself was potent on both 
species, results of the experiments show that it dramatically decreased enzyme activity. 
This supports the idea that it is the major constituent in both oils and is responsible for 
the enzyme activity being inhibited. With rabbit, 50% inhibition with tarragon occurred 
with 9.2 µg/mL, with basil at 13.8 µg/mL, and with estragole at 64µM. The potency of 
the inhibitors were increased with the human liver CYP2A6. With human, 50% 
inhibition with tarragon occurred at 4.6 µg/mL, with basil at 9.2 µg/mL, and estragole 
with 32 µM. The human liver microsomes were more sensitive than the rabbit liver 
microsomes. Table 3 shows the IC50 values for each respective inhibitor with both 
species. 
 
Table 4. IC50 Values for Inhibitors with CYP2A6. 
 
 Tarragon Basil Estragole 
Human Liver 
CYP2A6- IC50 
4.6 µg/mL 9.2 µg/mL 32 µM 
Rabbit Liver 
CYP2A6- IC50 
9.2 µg/mL 13.8 µg/mL 64 µM 
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Figure 23-A. Dose Response Studies with CYP2A6-Rabbit Liver. 
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Figure 23-B. Dose Response Studies with CYP2A6-Human Liver. 
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3.2.2 Michaelis-Menten Studies-CYP2A6 
 To study the kinetics of the enzyme, Michaelis-Menten studies were carried out. 
This model was used to find the mode of inhibtion by the inhibitors on the enzyme, 
CYP2A6. The kinetic study was carried out with different concentrations of the substrate, 
coumarin, ranging from 1 µM-10 µM in the presence and absence of the inhibitor. The 
concentration of inhibitors used was determined based on previous studies carried out 
where the enzyme activity is inhibited by 50%. The reactions were carried out in 
duplicates in order to confirm the results were reproducible. The study was carried out 
with both human and rabbit liver microsomes with tarragon oil, basil oil, and estragole. 
The data generated with the Michaelis-Menten graph was used to determine Vmax, 
Vmaxapp, Km and Kmapp and from this information KI was calculated. 
Figure 24 shows the Michaelis-Menten graph of human liver micrsomes with the 
presence and absence of inhibitor. Vmax for the reaction without the inhibitor was 103AU. 
When the essential oils and estragole was added to the reaction, there was a decrease in 
Vmaxapp. The Vmaxapp for the inhibitors were as follows: tarragon, 47 AU, basil, 46 AU, and 
estragole, 43 AU. The Km values of the reaction stayed in approximately the same range, 
with no inhibitor in reaction Km: 6.5 mM, tarragon Km: 5.0 mM, basil Km: 3.7 mM, and 
estragole Km: 5.0 mM. Vmax being reduced in the reaction and Km remaining in the same 
suggests that the inhibition is non-competitive. Using equation 2, the KI values were 
calculated for each inhibitor, KI values were calculated as follows, tarragon: 4.8 µg/mL, 
basil: 4.6 µg/mL, and estragole: 27.5 µM. 
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Figure 24. Michaelis-Menten Plot for CYP2A6-Human Liver. The graph is showing 
data of human liver enzyme with the presence and absence of inhibitor. 
 
 
 Michaelis-Menten studies were carried out with rabbit liver CYP2A6. Figure 25 
shows the results of these studies. The Vmax for the reaction with no inhibitor was 113.24. 
With the addition of tarragon, basil, and estragole, the Vmaxapp decreased. The values for 
Vmaxapp are as follows: tarragon: 72 AU, basil: 74 AU, and estragole: 63 AU. The Km 
values of the reaction stayed in approximately the same range, with no inhibitor in 
reaction the value of Km was: 6.0 µM, tarragon Km: 7.1 µM, basil Km: 5.9 µM, and 
estragole Km: 8.3. µM Using equation 2, the KI values were calculated for each inhibitor, 
KI values are as followed, tarragon: 9.9 µg/mL, basil: 10.8 µg/mL, and estragole: 49.3 
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µM. Again here the Vmax is changing, and the Km values are staying within the same 
range suggesting that it is a non-competitive inhibition. The KI values are higher then the 
human CYP2A6 values, suggesting that the inhibitor is less potent on rabbits verses 
humans (for comparative analysis, Vmax, Km, and KI values of both species can be found 
in table 5). 
 
 
Figure 25. Michaelis-Menten Plot for CYP2A6-Rabbit Liver. Graph showing results 
of rabbit liver microsomes with the presence and absence of tarragon, basil, and 
estragole. 
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Table 5. Comparative Analysis Showing Values of Vmax, Km, and KI-CYP2A6. 
 
 
 
 
3.2.3 Time Dependent Study Results 
 To determine the mode of inhibition, time-dependent studies were performed with 
the essential oils. Figure 26A-B shows the results of these studies. The reaction was 
carried out over the course of 80 minutes with the reactions being quenched at 10, 20, 40, 
60, and 80 minutes. This reaction process was done to determine if there was enzyme 
inactivation by the inhibitor over the course of the run of the reaction. If the inhibitor is 
irreversibly binding to the enzyme then, as discussed in the previous section, an increase 
in the rate of activity loss should be observed in the presence of the inhibitor. If the 
inhibitor binding to the enzyme is reversible then the rate at which activity loss occurs 
should be comparable with or without inhibitor, as measured by the ratio of product 
formation without/with inhibitor at each time point. The results of this study show that 
the inhibitor appears to be reversible because the inhibitor does not influence the rate at 
which activity decreases over time.  
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Figure 26-A. Time-Dependent Studies Graph-CYP2A6-Human Liver. Time-
Dependent studies graph with human liver microsomes with the absence and presence of 
inhibitor. 
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Figure 26-B. Time-Dependent Studies Graph-CYP2A6-Rabbit Liver. Time-
dependent studies with rabbit liver microsomes and the impact of the inhibitor overtime. 
 
 
3.3.0 Supersome Studies-CYP2E1 and CYP2A6 
 To confirm the results of the study, selectively expressed CYP P450 supersomes 
were used. CYP2A6 and CYP2E1 supersomes were used in a dose-response and time-
dependent studies. The overall reaction setup for both experiments is the same as 
mentioned above for time-dependent and dose response experiments using the human 
liver samples. The results of the dose response study with both enzymes can be seen in 
figure 27A-B. The results are similar to the dose response studies with both enzymes in 
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human, rabbit, and rat.  In other words, pure estragole appeared to be most potent 
followed by tarragon and then basil oils. 
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Figure 27-A. Dose Response Studies with Supersomes-CYP2E1. 
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Figure 27-B. Dose Response Studies with Supersomes-CYP2A6. 
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With CYP2E1 supersomes, 50% of the inhibition with tarragon occurred with 
9.2µg/mL, with basil ~13.2 µg/mL, and with estragole 64 µM. With CYP2A6 
supersomes, 50% of the inhibition with tarragon occurred with 4.6 µg/mL, with basil 9.2 
µg/mL, and with estragole 32 µM. The time-dependent studies with the supersomes also 
showed similar results as the studies done with the human, rabbit, and rat. Figure 28A-B 
shows the results of this experiment. Here again, the enzyme is not being inactivated over 
time, again showing that the inhibitors undergo a reversible reaction. 
 
 
Figure 28-A. Time-Dependent Studies with Supersomes-CYP2E1. 
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Figure 28-B. Time-Dependent Studies with Supersomes-CYP2A6. 
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CHAPTER IV 
CONCLUSION 
 
 
 This study investigated the inhibitory properties of essential oils on cytochrome 
P450 enzymes. The findings from this study show that tarragon and basil inhibit both 
enzymes through a reversible interaction. Estragole being the main constituent within 
these two oils, it can be said that it is the reason why the inhibition is happening. As 
predicted the oil with the greater concentration of estragole would inhibit the P450s most. 
Basil oil has a lower concentration of estragole and this is seen through the results of the 
studies, thus more of it was required to inhibit enzyme activity by 50%. Tarragon has a 
higher concentration of estragole, thus required a lower concentration to inhibit the 
enzyme activity by 50%. Supersomes were also used to confirm the inhibitory affect by 
these essential oils and the results from those studies followed the same pattern as the 
liver microsomes of human, rabbit, and rat. 
 It is important to understand what is happening mechanistically with the reaction. 
Initially it was thought that the terminal olefin was the reason why the enzyme was being 
inhibited; as mentioned before terminal olefins are considered “suicide inhibitors” 
meaning that the inhibitor reaction with the enzyme would be irreversible. As the data 
has shown, this is not an irreversible reaction but a reversible one. Mechanistically this 
inhibition reaction could be happening by the estragole coming into the active site of the 
enzyme (for both CYP2E1 and CYP2A6) with its methoxy pointing inwards and the
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terminal olefin facing the opposite direction from the activated oxygen. The methoxy 
group would then undergo hydroxylation followed by an o-demethylation reaction, 
producing an alcohol and formaldehyde as an end products.  Based on this hypothesis, 
future studies are aimed at detection of the predicted products of O-demethylation, 
namely chavicol (p-allylphenol) and formaldehyde. This would provide very strong 
support to the model in which the binding orientation of estragole was with the methoxy 
group, rather than the olefin, presented to the heme.  The active sites of the 2E1 and 2A6 
enzymes are also very small and restrictive, unlike most liver P450 isoforms, so rotation 
of estragole within the confines of this active site may not be possible.   
 CYP2E1 and CYP2A6 have both been implicated in peroxide production, along 
with the activation of a number of environmental toxins, which can lead to cancer. It may 
therefore be beneficial to inhibit these enzymes when certain xenobiotics enter living 
organisms. The inhibition of these enzymes has been shown with tarragon and basil 
essential oils, and further studies need to be carried out to determine the mechanism of 
the reaction to better understand this interaction, along with their potential health 
benefits. Understanding the metabolism of these essential oils at the mechanistic level 
will further improve the biochemical knowledge of how these essential oils may help in 
preventing the deleterious effects of these cytochrome P450 enzymes and the promotion 
of human health. 
 According to FEMA the average daily intake of estragole of a 60 kg human is 70 
µg, suggesting that the concentration required to inhibit the P450s described in the 
current study is easily achievable. A study done by Chen and his colleagues in 2007 
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showed that metabolized products of estragole were detected in humans at concentration 
of 1 µg/kg27. The physiological relevance of these studies shows that at low 
concentrations estragole can be potentially bioactivated by P450 enzymes. Furthermore 
metabolism of estragole by CYP P450 enzymes leads to the formation of 1-
sulfooxyestragole, a carbonium ion, which can bind to DNA and proteins and potentially 
cause cancer.
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